truseq custom amplicon panel Search Results


brca dna repair panel truseq custom amplicon lowinput panel  (Illumina Inc)
99
Illumina Inc brca dna repair panel truseq custom amplicon lowinput panel
Comparison of normalized coverage of targeted capture-based NGS and multiplex PCR-based NGS in control blood and diagnostic FFPE tumor samples. a Normalized coverage (y-axis) of targeted capture-based and multiplex PCR-based NGS at single-base resolution along all concatenated BRCA1/2 targets (x-axis) of five blood control samples (Additional file : Table S2, K1 to K5). The five blood samples are color-coded. The vertical green line indicates the end of <t>BRCA</t> 1 targets and the start of the BRCA 2 targets (target number is increasing from left to right which corresponds to five to three prime orientation of the gene). The horizontal green line displays normalized coverage of 1.0. All target exons are separated via gray dotted vertical lines. Selected target exons are marked. Exemplary, two randomly chosen <t>amplicon</t> dropouts are marked by a red arrow. b Normalized coverage (y-axis) of targeted capture-based and multiplex PCR-based NGS of FFPE samples from patient 1 to 15 (Additional file : Table S2, P01 to P15) at single-base resolution along all concatenated BRCA1/2 targets (x-axis) Samples P1 to P13 are color encoded in blue. Exemplary, randomly chosen capture target dropouts and amplicon dropouts are marked by a red arrow. The vertical green line indicates the end of the BRCA2 targets (target number is increasing from left to right which corresponds to five to three prime orientation of the gene) and the start of the BRCA1 targets (decreasing from left to right). The horizontal green line displays normalized coverage of 1.0. All target exons are separated by gray dotted vertical lines. Selected target exons are marked. Exemplary, two randomly chosen amplicon dropouts are marked with a red arrow. c To illustrate the advantages of the targeted capture-based protocol over the multiplex PCR-based approach for analysis of low-quality <t>DNA</t> the normalized coverages (y-axis) of targets of capture-based and multiplex PCR-based NGS of two FFPE samples (P 5 and P10) are displayed at single-base resolution along all concatenated BRCA1/2 targets (x-axis). Exemplary, two randomly chosen amplicon dropouts are marked with a red arrow
Brca Dna Repair Panel Truseq Custom Amplicon Lowinput Panel, supplied by Illumina Inc, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/brca dna repair panel truseq custom amplicon lowinput panel/product/Illumina Inc
Average 99 stars, based on 1 article reviews
brca dna repair panel truseq custom amplicon lowinput panel - by Bioz Stars, 2026-03
99/100 stars
  Buy from Supplier
ch capture panel illumina truseq custom amplicon v.1.5  (Illumina Inc)
90
Illumina Inc ch capture panel illumina truseq custom amplicon v.1.5
Comparison of normalized coverage of targeted capture-based NGS and multiplex PCR-based NGS in control blood and diagnostic FFPE tumor samples. a Normalized coverage (y-axis) of targeted capture-based and multiplex PCR-based NGS at single-base resolution along all concatenated BRCA1/2 targets (x-axis) of five blood control samples (Additional file : Table S2, K1 to K5). The five blood samples are color-coded. The vertical green line indicates the end of <t>BRCA</t> 1 targets and the start of the BRCA 2 targets (target number is increasing from left to right which corresponds to five to three prime orientation of the gene). The horizontal green line displays normalized coverage of 1.0. All target exons are separated via gray dotted vertical lines. Selected target exons are marked. Exemplary, two randomly chosen <t>amplicon</t> dropouts are marked by a red arrow. b Normalized coverage (y-axis) of targeted capture-based and multiplex PCR-based NGS of FFPE samples from patient 1 to 15 (Additional file : Table S2, P01 to P15) at single-base resolution along all concatenated BRCA1/2 targets (x-axis) Samples P1 to P13 are color encoded in blue. Exemplary, randomly chosen capture target dropouts and amplicon dropouts are marked by a red arrow. The vertical green line indicates the end of the BRCA2 targets (target number is increasing from left to right which corresponds to five to three prime orientation of the gene) and the start of the BRCA1 targets (decreasing from left to right). The horizontal green line displays normalized coverage of 1.0. All target exons are separated by gray dotted vertical lines. Selected target exons are marked. Exemplary, two randomly chosen amplicon dropouts are marked with a red arrow. c To illustrate the advantages of the targeted capture-based protocol over the multiplex PCR-based approach for analysis of low-quality <t>DNA</t> the normalized coverages (y-axis) of targets of capture-based and multiplex PCR-based NGS of two FFPE samples (P 5 and P10) are displayed at single-base resolution along all concatenated BRCA1/2 targets (x-axis). Exemplary, two randomly chosen amplicon dropouts are marked with a red arrow
Ch Capture Panel Illumina Truseq Custom Amplicon V.1.5, supplied by Illumina Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ch capture panel illumina truseq custom amplicon v.1.5/product/Illumina Inc
Average 90 stars, based on 1 article reviews
ch capture panel illumina truseq custom amplicon v.1.5 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
amplicon-based custom targeted next-generation sequencing panel for 33 hematologic malignancy-associated genes truseq custom amplicon  (Illumina Inc)
90
Illumina Inc amplicon-based custom targeted next-generation sequencing panel for 33 hematologic malignancy-associated genes truseq custom amplicon
Comparison of normalized coverage of targeted capture-based NGS and multiplex PCR-based NGS in control blood and diagnostic FFPE tumor samples. a Normalized coverage (y-axis) of targeted capture-based and multiplex PCR-based NGS at single-base resolution along all concatenated BRCA1/2 targets (x-axis) of five blood control samples (Additional file : Table S2, K1 to K5). The five blood samples are color-coded. The vertical green line indicates the end of <t>BRCA</t> 1 targets and the start of the BRCA 2 targets (target number is increasing from left to right which corresponds to five to three prime orientation of the gene). The horizontal green line displays normalized coverage of 1.0. All target exons are separated via gray dotted vertical lines. Selected target exons are marked. Exemplary, two randomly chosen <t>amplicon</t> dropouts are marked by a red arrow. b Normalized coverage (y-axis) of targeted capture-based and multiplex PCR-based NGS of FFPE samples from patient 1 to 15 (Additional file : Table S2, P01 to P15) at single-base resolution along all concatenated BRCA1/2 targets (x-axis) Samples P1 to P13 are color encoded in blue. Exemplary, randomly chosen capture target dropouts and amplicon dropouts are marked by a red arrow. The vertical green line indicates the end of the BRCA2 targets (target number is increasing from left to right which corresponds to five to three prime orientation of the gene) and the start of the BRCA1 targets (decreasing from left to right). The horizontal green line displays normalized coverage of 1.0. All target exons are separated by gray dotted vertical lines. Selected target exons are marked. Exemplary, two randomly chosen amplicon dropouts are marked with a red arrow. c To illustrate the advantages of the targeted capture-based protocol over the multiplex PCR-based approach for analysis of low-quality <t>DNA</t> the normalized coverages (y-axis) of targets of capture-based and multiplex PCR-based NGS of two FFPE samples (P 5 and P10) are displayed at single-base resolution along all concatenated BRCA1/2 targets (x-axis). Exemplary, two randomly chosen amplicon dropouts are marked with a red arrow
Amplicon Based Custom Targeted Next Generation Sequencing Panel For 33 Hematologic Malignancy Associated Genes Truseq Custom Amplicon, supplied by Illumina Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/amplicon-based custom targeted next-generation sequencing panel for 33 hematologic malignancy-associated genes truseq custom amplicon/product/Illumina Inc
Average 90 stars, based on 1 article reviews
amplicon-based custom targeted next-generation sequencing panel for 33 hematologic malignancy-associated genes truseq custom amplicon - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
brca dna repair panel / truseq custom amplicon lowinput panel kit  (Illumina Inc)
90
Illumina Inc brca dna repair panel / truseq custom amplicon lowinput panel kit
Comparison of normalized coverage of targeted capture-based NGS and multiplex PCR-based NGS in control blood and diagnostic FFPE tumor samples. a Normalized coverage (y-axis) of targeted capture-based and multiplex PCR-based NGS at single-base resolution along all concatenated BRCA1/2 targets (x-axis) of five blood control samples (Additional file : Table S2, K1 to K5). The five blood samples are color-coded. The vertical green line indicates the end of <t>BRCA</t> 1 targets and the start of the BRCA 2 targets (target number is increasing from left to right which corresponds to five to three prime orientation of the gene). The horizontal green line displays normalized coverage of 1.0. All target exons are separated via gray dotted vertical lines. Selected target exons are marked. Exemplary, two randomly chosen <t>amplicon</t> dropouts are marked by a red arrow. b Normalized coverage (y-axis) of targeted capture-based and multiplex PCR-based NGS of FFPE samples from patient 1 to 15 (Additional file : Table S2, P01 to P15) at single-base resolution along all concatenated BRCA1/2 targets (x-axis) Samples P1 to P13 are color encoded in blue. Exemplary, randomly chosen capture target dropouts and amplicon dropouts are marked by a red arrow. The vertical green line indicates the end of the BRCA2 targets (target number is increasing from left to right which corresponds to five to three prime orientation of the gene) and the start of the BRCA1 targets (decreasing from left to right). The horizontal green line displays normalized coverage of 1.0. All target exons are separated by gray dotted vertical lines. Selected target exons are marked. Exemplary, two randomly chosen amplicon dropouts are marked with a red arrow. c To illustrate the advantages of the targeted capture-based protocol over the multiplex PCR-based approach for analysis of low-quality <t>DNA</t> the normalized coverages (y-axis) of targets of capture-based and multiplex PCR-based NGS of two FFPE samples (P 5 and P10) are displayed at single-base resolution along all concatenated BRCA1/2 targets (x-axis). Exemplary, two randomly chosen amplicon dropouts are marked with a red arrow
Brca Dna Repair Panel / Truseq Custom Amplicon Lowinput Panel Kit, supplied by Illumina Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/brca dna repair panel / truseq custom amplicon lowinput panel kit/product/Illumina Inc
Average 90 stars, based on 1 article reviews
brca dna repair panel / truseq custom amplicon lowinput panel kit - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
12-gene custom ngs panel truseq custom amplicon low input  (Illumina Inc)
90
Illumina Inc 12-gene custom ngs panel truseq custom amplicon low input
Comparison of normalized coverage of targeted capture-based NGS and multiplex PCR-based NGS in control blood and diagnostic FFPE tumor samples. a Normalized coverage (y-axis) of targeted capture-based and multiplex PCR-based NGS at single-base resolution along all concatenated BRCA1/2 targets (x-axis) of five blood control samples (Additional file : Table S2, K1 to K5). The five blood samples are color-coded. The vertical green line indicates the end of <t>BRCA</t> 1 targets and the start of the BRCA 2 targets (target number is increasing from left to right which corresponds to five to three prime orientation of the gene). The horizontal green line displays normalized coverage of 1.0. All target exons are separated via gray dotted vertical lines. Selected target exons are marked. Exemplary, two randomly chosen <t>amplicon</t> dropouts are marked by a red arrow. b Normalized coverage (y-axis) of targeted capture-based and multiplex PCR-based NGS of FFPE samples from patient 1 to 15 (Additional file : Table S2, P01 to P15) at single-base resolution along all concatenated BRCA1/2 targets (x-axis) Samples P1 to P13 are color encoded in blue. Exemplary, randomly chosen capture target dropouts and amplicon dropouts are marked by a red arrow. The vertical green line indicates the end of the BRCA2 targets (target number is increasing from left to right which corresponds to five to three prime orientation of the gene) and the start of the BRCA1 targets (decreasing from left to right). The horizontal green line displays normalized coverage of 1.0. All target exons are separated by gray dotted vertical lines. Selected target exons are marked. Exemplary, two randomly chosen amplicon dropouts are marked with a red arrow. c To illustrate the advantages of the targeted capture-based protocol over the multiplex PCR-based approach for analysis of low-quality <t>DNA</t> the normalized coverages (y-axis) of targets of capture-based and multiplex PCR-based NGS of two FFPE samples (P 5 and P10) are displayed at single-base resolution along all concatenated BRCA1/2 targets (x-axis). Exemplary, two randomly chosen amplicon dropouts are marked with a red arrow
12 Gene Custom Ngs Panel Truseq Custom Amplicon Low Input, supplied by Illumina Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/12-gene custom ngs panel truseq custom amplicon low input/product/Illumina Inc
Average 90 stars, based on 1 article reviews
12-gene custom ngs panel truseq custom amplicon low input - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
dystonia panel truseq custom amplicon assay 1.5  (Illumina Inc)
90
Illumina Inc dystonia panel truseq custom amplicon assay 1.5
Comparison of normalized coverage of targeted capture-based NGS and multiplex PCR-based NGS in control blood and diagnostic FFPE tumor samples. a Normalized coverage (y-axis) of targeted capture-based and multiplex PCR-based NGS at single-base resolution along all concatenated BRCA1/2 targets (x-axis) of five blood control samples (Additional file : Table S2, K1 to K5). The five blood samples are color-coded. The vertical green line indicates the end of <t>BRCA</t> 1 targets and the start of the BRCA 2 targets (target number is increasing from left to right which corresponds to five to three prime orientation of the gene). The horizontal green line displays normalized coverage of 1.0. All target exons are separated via gray dotted vertical lines. Selected target exons are marked. Exemplary, two randomly chosen <t>amplicon</t> dropouts are marked by a red arrow. b Normalized coverage (y-axis) of targeted capture-based and multiplex PCR-based NGS of FFPE samples from patient 1 to 15 (Additional file : Table S2, P01 to P15) at single-base resolution along all concatenated BRCA1/2 targets (x-axis) Samples P1 to P13 are color encoded in blue. Exemplary, randomly chosen capture target dropouts and amplicon dropouts are marked by a red arrow. The vertical green line indicates the end of the BRCA2 targets (target number is increasing from left to right which corresponds to five to three prime orientation of the gene) and the start of the BRCA1 targets (decreasing from left to right). The horizontal green line displays normalized coverage of 1.0. All target exons are separated by gray dotted vertical lines. Selected target exons are marked. Exemplary, two randomly chosen amplicon dropouts are marked with a red arrow. c To illustrate the advantages of the targeted capture-based protocol over the multiplex PCR-based approach for analysis of low-quality <t>DNA</t> the normalized coverages (y-axis) of targets of capture-based and multiplex PCR-based NGS of two FFPE samples (P 5 and P10) are displayed at single-base resolution along all concatenated BRCA1/2 targets (x-axis). Exemplary, two randomly chosen amplicon dropouts are marked with a red arrow
Dystonia Panel Truseq Custom Amplicon Assay 1.5, supplied by Illumina Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/dystonia panel truseq custom amplicon assay 1.5/product/Illumina Inc
Average 90 stars, based on 1 article reviews
dystonia panel truseq custom amplicon assay 1.5 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
customized gene panel truseq custom amplicon  (Illumina Inc)
90
Illumina Inc customized gene panel truseq custom amplicon
Comparison of normalized coverage of targeted capture-based NGS and multiplex PCR-based NGS in control blood and diagnostic FFPE tumor samples. a Normalized coverage (y-axis) of targeted capture-based and multiplex PCR-based NGS at single-base resolution along all concatenated BRCA1/2 targets (x-axis) of five blood control samples (Additional file : Table S2, K1 to K5). The five blood samples are color-coded. The vertical green line indicates the end of <t>BRCA</t> 1 targets and the start of the BRCA 2 targets (target number is increasing from left to right which corresponds to five to three prime orientation of the gene). The horizontal green line displays normalized coverage of 1.0. All target exons are separated via gray dotted vertical lines. Selected target exons are marked. Exemplary, two randomly chosen <t>amplicon</t> dropouts are marked by a red arrow. b Normalized coverage (y-axis) of targeted capture-based and multiplex PCR-based NGS of FFPE samples from patient 1 to 15 (Additional file : Table S2, P01 to P15) at single-base resolution along all concatenated BRCA1/2 targets (x-axis) Samples P1 to P13 are color encoded in blue. Exemplary, randomly chosen capture target dropouts and amplicon dropouts are marked by a red arrow. The vertical green line indicates the end of the BRCA2 targets (target number is increasing from left to right which corresponds to five to three prime orientation of the gene) and the start of the BRCA1 targets (decreasing from left to right). The horizontal green line displays normalized coverage of 1.0. All target exons are separated by gray dotted vertical lines. Selected target exons are marked. Exemplary, two randomly chosen amplicon dropouts are marked with a red arrow. c To illustrate the advantages of the targeted capture-based protocol over the multiplex PCR-based approach for analysis of low-quality <t>DNA</t> the normalized coverages (y-axis) of targets of capture-based and multiplex PCR-based NGS of two FFPE samples (P 5 and P10) are displayed at single-base resolution along all concatenated BRCA1/2 targets (x-axis). Exemplary, two randomly chosen amplicon dropouts are marked with a red arrow
Customized Gene Panel Truseq Custom Amplicon, supplied by Illumina Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/customized gene panel truseq custom amplicon/product/Illumina Inc
Average 90 stars, based on 1 article reviews
customized gene panel truseq custom amplicon - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
dragon targeted gene sequencing panel illumina_truseq custom amplicon  (Illumina Inc)
90
Illumina Inc dragon targeted gene sequencing panel illumina_truseq custom amplicon
Comparison of normalized coverage of targeted capture-based NGS and multiplex PCR-based NGS in control blood and diagnostic FFPE tumor samples. a Normalized coverage (y-axis) of targeted capture-based and multiplex PCR-based NGS at single-base resolution along all concatenated BRCA1/2 targets (x-axis) of five blood control samples (Additional file : Table S2, K1 to K5). The five blood samples are color-coded. The vertical green line indicates the end of <t>BRCA</t> 1 targets and the start of the BRCA 2 targets (target number is increasing from left to right which corresponds to five to three prime orientation of the gene). The horizontal green line displays normalized coverage of 1.0. All target exons are separated via gray dotted vertical lines. Selected target exons are marked. Exemplary, two randomly chosen <t>amplicon</t> dropouts are marked by a red arrow. b Normalized coverage (y-axis) of targeted capture-based and multiplex PCR-based NGS of FFPE samples from patient 1 to 15 (Additional file : Table S2, P01 to P15) at single-base resolution along all concatenated BRCA1/2 targets (x-axis) Samples P1 to P13 are color encoded in blue. Exemplary, randomly chosen capture target dropouts and amplicon dropouts are marked by a red arrow. The vertical green line indicates the end of the BRCA2 targets (target number is increasing from left to right which corresponds to five to three prime orientation of the gene) and the start of the BRCA1 targets (decreasing from left to right). The horizontal green line displays normalized coverage of 1.0. All target exons are separated by gray dotted vertical lines. Selected target exons are marked. Exemplary, two randomly chosen amplicon dropouts are marked with a red arrow. c To illustrate the advantages of the targeted capture-based protocol over the multiplex PCR-based approach for analysis of low-quality <t>DNA</t> the normalized coverages (y-axis) of targets of capture-based and multiplex PCR-based NGS of two FFPE samples (P 5 and P10) are displayed at single-base resolution along all concatenated BRCA1/2 targets (x-axis). Exemplary, two randomly chosen amplicon dropouts are marked with a red arrow
Dragon Targeted Gene Sequencing Panel Illumina Truseq Custom Amplicon, supplied by Illumina Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/dragon targeted gene sequencing panel illumina_truseq custom amplicon/product/Illumina Inc
Average 90 stars, based on 1 article reviews
dragon targeted gene sequencing panel illumina_truseq custom amplicon - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
truseq custom amplicon lymphoid panel  (Illumina Inc)
90
Illumina Inc truseq custom amplicon lymphoid panel
Comparison of normalized coverage of targeted capture-based NGS and multiplex PCR-based NGS in control blood and diagnostic FFPE tumor samples. a Normalized coverage (y-axis) of targeted capture-based and multiplex PCR-based NGS at single-base resolution along all concatenated BRCA1/2 targets (x-axis) of five blood control samples (Additional file : Table S2, K1 to K5). The five blood samples are color-coded. The vertical green line indicates the end of <t>BRCA</t> 1 targets and the start of the BRCA 2 targets (target number is increasing from left to right which corresponds to five to three prime orientation of the gene). The horizontal green line displays normalized coverage of 1.0. All target exons are separated via gray dotted vertical lines. Selected target exons are marked. Exemplary, two randomly chosen <t>amplicon</t> dropouts are marked by a red arrow. b Normalized coverage (y-axis) of targeted capture-based and multiplex PCR-based NGS of FFPE samples from patient 1 to 15 (Additional file : Table S2, P01 to P15) at single-base resolution along all concatenated BRCA1/2 targets (x-axis) Samples P1 to P13 are color encoded in blue. Exemplary, randomly chosen capture target dropouts and amplicon dropouts are marked by a red arrow. The vertical green line indicates the end of the BRCA2 targets (target number is increasing from left to right which corresponds to five to three prime orientation of the gene) and the start of the BRCA1 targets (decreasing from left to right). The horizontal green line displays normalized coverage of 1.0. All target exons are separated by gray dotted vertical lines. Selected target exons are marked. Exemplary, two randomly chosen amplicon dropouts are marked with a red arrow. c To illustrate the advantages of the targeted capture-based protocol over the multiplex PCR-based approach for analysis of low-quality <t>DNA</t> the normalized coverages (y-axis) of targets of capture-based and multiplex PCR-based NGS of two FFPE samples (P 5 and P10) are displayed at single-base resolution along all concatenated BRCA1/2 targets (x-axis). Exemplary, two randomly chosen amplicon dropouts are marked with a red arrow
Truseq Custom Amplicon Lymphoid Panel, supplied by Illumina Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/truseq custom amplicon lymphoid panel/product/Illumina Inc
Average 90 stars, based on 1 article reviews
truseq custom amplicon lymphoid panel - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
truseq custom amplicon panel targeting 33 swi/snf genes  (Illumina Inc)
90
Illumina Inc truseq custom amplicon panel targeting 33 swi/snf genes
Comparison of normalized coverage of targeted capture-based NGS and multiplex PCR-based NGS in control blood and diagnostic FFPE tumor samples. a Normalized coverage (y-axis) of targeted capture-based and multiplex PCR-based NGS at single-base resolution along all concatenated BRCA1/2 targets (x-axis) of five blood control samples (Additional file : Table S2, K1 to K5). The five blood samples are color-coded. The vertical green line indicates the end of <t>BRCA</t> 1 targets and the start of the BRCA 2 targets (target number is increasing from left to right which corresponds to five to three prime orientation of the gene). The horizontal green line displays normalized coverage of 1.0. All target exons are separated via gray dotted vertical lines. Selected target exons are marked. Exemplary, two randomly chosen <t>amplicon</t> dropouts are marked by a red arrow. b Normalized coverage (y-axis) of targeted capture-based and multiplex PCR-based NGS of FFPE samples from patient 1 to 15 (Additional file : Table S2, P01 to P15) at single-base resolution along all concatenated BRCA1/2 targets (x-axis) Samples P1 to P13 are color encoded in blue. Exemplary, randomly chosen capture target dropouts and amplicon dropouts are marked by a red arrow. The vertical green line indicates the end of the BRCA2 targets (target number is increasing from left to right which corresponds to five to three prime orientation of the gene) and the start of the BRCA1 targets (decreasing from left to right). The horizontal green line displays normalized coverage of 1.0. All target exons are separated by gray dotted vertical lines. Selected target exons are marked. Exemplary, two randomly chosen amplicon dropouts are marked with a red arrow. c To illustrate the advantages of the targeted capture-based protocol over the multiplex PCR-based approach for analysis of low-quality <t>DNA</t> the normalized coverages (y-axis) of targets of capture-based and multiplex PCR-based NGS of two FFPE samples (P 5 and P10) are displayed at single-base resolution along all concatenated BRCA1/2 targets (x-axis). Exemplary, two randomly chosen amplicon dropouts are marked with a red arrow
Truseq Custom Amplicon Panel Targeting 33 Swi/Snf Genes, supplied by Illumina Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/truseq custom amplicon panel targeting 33 swi/snf genes/product/Illumina Inc
Average 90 stars, based on 1 article reviews
truseq custom amplicon panel targeting 33 swi/snf genes - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
dna sequencing analysis with an illumina truseq custom amplicon panel  (Illumina Inc)
90
Illumina Inc dna sequencing analysis with an illumina truseq custom amplicon panel
Comparison of normalized coverage of targeted capture-based NGS and multiplex PCR-based NGS in control blood and diagnostic FFPE tumor samples. a Normalized coverage (y-axis) of targeted capture-based and multiplex PCR-based NGS at single-base resolution along all concatenated BRCA1/2 targets (x-axis) of five blood control samples (Additional file : Table S2, K1 to K5). The five blood samples are color-coded. The vertical green line indicates the end of <t>BRCA</t> 1 targets and the start of the BRCA 2 targets (target number is increasing from left to right which corresponds to five to three prime orientation of the gene). The horizontal green line displays normalized coverage of 1.0. All target exons are separated via gray dotted vertical lines. Selected target exons are marked. Exemplary, two randomly chosen <t>amplicon</t> dropouts are marked by a red arrow. b Normalized coverage (y-axis) of targeted capture-based and multiplex PCR-based NGS of FFPE samples from patient 1 to 15 (Additional file : Table S2, P01 to P15) at single-base resolution along all concatenated BRCA1/2 targets (x-axis) Samples P1 to P13 are color encoded in blue. Exemplary, randomly chosen capture target dropouts and amplicon dropouts are marked by a red arrow. The vertical green line indicates the end of the BRCA2 targets (target number is increasing from left to right which corresponds to five to three prime orientation of the gene) and the start of the BRCA1 targets (decreasing from left to right). The horizontal green line displays normalized coverage of 1.0. All target exons are separated by gray dotted vertical lines. Selected target exons are marked. Exemplary, two randomly chosen amplicon dropouts are marked with a red arrow. c To illustrate the advantages of the targeted capture-based protocol over the multiplex PCR-based approach for analysis of low-quality <t>DNA</t> the normalized coverages (y-axis) of targets of capture-based and multiplex PCR-based NGS of two FFPE samples (P 5 and P10) are displayed at single-base resolution along all concatenated BRCA1/2 targets (x-axis). Exemplary, two randomly chosen amplicon dropouts are marked with a red arrow
Dna Sequencing Analysis With An Illumina Truseq Custom Amplicon Panel, supplied by Illumina Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/dna sequencing analysis with an illumina truseq custom amplicon panel/product/Illumina Inc
Average 90 stars, based on 1 article reviews
dna sequencing analysis with an illumina truseq custom amplicon panel - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
amplicon-based next-generation sequencing panel truseq custom amplicon kit  (Illumina Inc)
90
Illumina Inc amplicon-based next-generation sequencing panel truseq custom amplicon kit
Comparison of normalized coverage of targeted capture-based NGS and multiplex PCR-based NGS in control blood and diagnostic FFPE tumor samples. a Normalized coverage (y-axis) of targeted capture-based and multiplex PCR-based NGS at single-base resolution along all concatenated BRCA1/2 targets (x-axis) of five blood control samples (Additional file : Table S2, K1 to K5). The five blood samples are color-coded. The vertical green line indicates the end of <t>BRCA</t> 1 targets and the start of the BRCA 2 targets (target number is increasing from left to right which corresponds to five to three prime orientation of the gene). The horizontal green line displays normalized coverage of 1.0. All target exons are separated via gray dotted vertical lines. Selected target exons are marked. Exemplary, two randomly chosen <t>amplicon</t> dropouts are marked by a red arrow. b Normalized coverage (y-axis) of targeted capture-based and multiplex PCR-based NGS of FFPE samples from patient 1 to 15 (Additional file : Table S2, P01 to P15) at single-base resolution along all concatenated BRCA1/2 targets (x-axis) Samples P1 to P13 are color encoded in blue. Exemplary, randomly chosen capture target dropouts and amplicon dropouts are marked by a red arrow. The vertical green line indicates the end of the BRCA2 targets (target number is increasing from left to right which corresponds to five to three prime orientation of the gene) and the start of the BRCA1 targets (decreasing from left to right). The horizontal green line displays normalized coverage of 1.0. All target exons are separated by gray dotted vertical lines. Selected target exons are marked. Exemplary, two randomly chosen amplicon dropouts are marked with a red arrow. c To illustrate the advantages of the targeted capture-based protocol over the multiplex PCR-based approach for analysis of low-quality <t>DNA</t> the normalized coverages (y-axis) of targets of capture-based and multiplex PCR-based NGS of two FFPE samples (P 5 and P10) are displayed at single-base resolution along all concatenated BRCA1/2 targets (x-axis). Exemplary, two randomly chosen amplicon dropouts are marked with a red arrow
Amplicon Based Next Generation Sequencing Panel Truseq Custom Amplicon Kit, supplied by Illumina Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/amplicon-based next-generation sequencing panel truseq custom amplicon kit/product/Illumina Inc
Average 90 stars, based on 1 article reviews
amplicon-based next-generation sequencing panel truseq custom amplicon kit - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


Comparison of normalized coverage of targeted capture-based NGS and multiplex PCR-based NGS in control blood and diagnostic FFPE tumor samples. a Normalized coverage (y-axis) of targeted capture-based and multiplex PCR-based NGS at single-base resolution along all concatenated BRCA1/2 targets (x-axis) of five blood control samples (Additional file : Table S2, K1 to K5). The five blood samples are color-coded. The vertical green line indicates the end of BRCA 1 targets and the start of the BRCA 2 targets (target number is increasing from left to right which corresponds to five to three prime orientation of the gene). The horizontal green line displays normalized coverage of 1.0. All target exons are separated via gray dotted vertical lines. Selected target exons are marked. Exemplary, two randomly chosen amplicon dropouts are marked by a red arrow. b Normalized coverage (y-axis) of targeted capture-based and multiplex PCR-based NGS of FFPE samples from patient 1 to 15 (Additional file : Table S2, P01 to P15) at single-base resolution along all concatenated BRCA1/2 targets (x-axis) Samples P1 to P13 are color encoded in blue. Exemplary, randomly chosen capture target dropouts and amplicon dropouts are marked by a red arrow. The vertical green line indicates the end of the BRCA2 targets (target number is increasing from left to right which corresponds to five to three prime orientation of the gene) and the start of the BRCA1 targets (decreasing from left to right). The horizontal green line displays normalized coverage of 1.0. All target exons are separated by gray dotted vertical lines. Selected target exons are marked. Exemplary, two randomly chosen amplicon dropouts are marked with a red arrow. c To illustrate the advantages of the targeted capture-based protocol over the multiplex PCR-based approach for analysis of low-quality DNA the normalized coverages (y-axis) of targets of capture-based and multiplex PCR-based NGS of two FFPE samples (P 5 and P10) are displayed at single-base resolution along all concatenated BRCA1/2 targets (x-axis). Exemplary, two randomly chosen amplicon dropouts are marked with a red arrow

Journal: BMC Cancer

Article Title: Targeted capture-based NGS is superior to multiplex PCR-based NGS for hereditary BRCA1 and BRCA2 gene analysis in FFPE tumor samples

doi: 10.1186/s12885-019-5584-6

Figure Lengend Snippet: Comparison of normalized coverage of targeted capture-based NGS and multiplex PCR-based NGS in control blood and diagnostic FFPE tumor samples. a Normalized coverage (y-axis) of targeted capture-based and multiplex PCR-based NGS at single-base resolution along all concatenated BRCA1/2 targets (x-axis) of five blood control samples (Additional file : Table S2, K1 to K5). The five blood samples are color-coded. The vertical green line indicates the end of BRCA 1 targets and the start of the BRCA 2 targets (target number is increasing from left to right which corresponds to five to three prime orientation of the gene). The horizontal green line displays normalized coverage of 1.0. All target exons are separated via gray dotted vertical lines. Selected target exons are marked. Exemplary, two randomly chosen amplicon dropouts are marked by a red arrow. b Normalized coverage (y-axis) of targeted capture-based and multiplex PCR-based NGS of FFPE samples from patient 1 to 15 (Additional file : Table S2, P01 to P15) at single-base resolution along all concatenated BRCA1/2 targets (x-axis) Samples P1 to P13 are color encoded in blue. Exemplary, randomly chosen capture target dropouts and amplicon dropouts are marked by a red arrow. The vertical green line indicates the end of the BRCA2 targets (target number is increasing from left to right which corresponds to five to three prime orientation of the gene) and the start of the BRCA1 targets (decreasing from left to right). The horizontal green line displays normalized coverage of 1.0. All target exons are separated by gray dotted vertical lines. Selected target exons are marked. Exemplary, two randomly chosen amplicon dropouts are marked with a red arrow. c To illustrate the advantages of the targeted capture-based protocol over the multiplex PCR-based approach for analysis of low-quality DNA the normalized coverages (y-axis) of targets of capture-based and multiplex PCR-based NGS of two FFPE samples (P 5 and P10) are displayed at single-base resolution along all concatenated BRCA1/2 targets (x-axis). Exemplary, two randomly chosen amplicon dropouts are marked with a red arrow

Article Snippet: For multiplex PCR-based NGS the BRCA DNA Repair Panel - TruSeq Custom Amplicon LowInput panel (Illumina, Inc.), referred to as multiplex PCR-based NGS in this study, was used.

Techniques: Comparison, Multiplex Assay, Diagnostic Assay, Amplification